Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury

Cardiovascular Research

Volumn 83, Issue 2, 2009, Pages 325-334

  Strande, Jennifer L ^a   Widlansky, Michael E ^a   Tsopanoglou, Nikos E ^b   Su, Jidong ^a   Wang, JingLi ^a   Hsu, Anna ^a   Routhu, Kasi V ^a   Baker, John E ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Cardioprotection; Cryptic peptide; Ischaemia; Reperfusion injury; Vasodilation

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE; PARSTATIN; PERTUSSIS TOXIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; DRUG INHIBITION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; GUANYLATE CYCLASE; HEART RATE; KATP CHANNELS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; POTASSIUM CHANNEL BLOCKERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-1; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TIME FACTORS; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 67650236404     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp122     Document Type: Article

References (41)

1. McLean PG, Aston D, Sarkar D, Ahluwalia A. Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. Circ Res 2002;90:465-472.
2. Reffelmann T, Hale SL, Li G, Kloner RA. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2002;282:H766-H772.
3. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001;37:367-374.
4. Meyer K, Schipke JD, Klocke RC, Gams E, Korbmacher B. Inotropic, vasodilating and preconditioning actions of levosimendan in the heart. Thorac Cardiovasc Surg 2008;56:379-385.
5. Sobey CG, Dalipram RA, Dusting GJ, Woodman OL. Impaired endothelium-dependent relaxation of dog coronary arteries after myocardial ischaemia and reperfusion: prevention by amlodipine, propranolol and allopurinol. Br J Pharmacol 1992;105:557-562.
6. Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol 2006;148:696- 702.
7. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol 2007;102:350-358.
8. Hamilton JR, Moffatt JD, Frauman AG, Cocks TM. Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. J Cardiovasc Pharmacol 2001;38:108-119.
9. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 2001;293:1666-1670.
10. Zania P, Gourni D, Aplin AC, Nicosia RF, Flordellis CS, Maragoudakis ME et al. Parstatin, the cleaved peptide on proteinase-activated receptor 1, is a potent inhibitor of angiogenesis. J Pharmacol Exp Ther 2009; 328:378-389.
11. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling. J Pharmacol Exp Ther 2008;324:1045-1054.
12. Lasley RD, Mentzer RM Jr. Protective effects of adenosine in the reversibly injured heart. Ann Thorac Surg 1995;60:843-846.
13. Schultz JEJ, Hsu AK, Barbieri JT, Li P-L, Gross GJ. Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in intact rat heart. Am J Physiol Heart Circ Physiol 1998;275:H495-H500.
14. Baker JE, Curry BD, Olinger GN, Gross GJ. Increased tolerance of the chronically hypoxic immature heart to ischemia. Contribution of the KATP channel. Circulation 1997;95:1278-1285.
15. Bosnjak JJ, Terata K, Miura H, Sato A, Nicolosi AC, McDonald M et al. Mechanism of thrombin-induced vasodilation in human coronary arterioles. Am J Physiol Heart Circ Physiol 2003;284:H1080-H1086.
16. Liu Y, Harder DR, Lombard JH. Myogenic activation of canine small renal arteries after nonchemical removal of the endothelium. Am J Physiol 1994;267:H302-H307.
17. Baker JE, Holman P, Gross GJ. Preconditioning in immature rabbit hearts: role of KATP channels. Circulation 1999;99:1249-1254.
18. Peart JN, Gross GJ. Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways. Am J Physiol Heart Circ Physiol 2006;291:H1746-H1753.
19. Sukhodub A, Jovanovic S, Du Q, Budas G, Clelland AK, Shen M et al. AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K(+) channels. J Cell Physiol 2007;210:224-236.
20. Budas GR, Sukhodub A, Alessi DR, Jovanovic A. 3'Phosphoinositide- dependent kinase-1 is essential for ischemic preconditioning of the myocardium. FASEB J 2006;20:2556-2558.
21. Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM. The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res Cardiol 2000;95:472-478.
22. Nakano A, Baines CP, Kim SO, Pelech SL, Downey JM, Cohen MV et al. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK. Circ Res 2000;86:144-151.
23. Weinbrenner C, Liu GS, Cohen MV, Downey JM. Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol 1997; 29:2383-2391.
24. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005;288:H971-H976.
25. Philipp S, Critz SD, Cui L, Solodushko V, Cohen MV, Downey JM. Localizing extracellular signal-regulated kinase (ERK) in pharmacological preconditioning's trigger pathway. Basic Res Cardiol 2006;101:159- 167.
26. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/ reperfusion injury. Circulation 2004;109:2050-2053.
27. Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD et al. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol 2004;286:H468-H476.
28. Krieg T, Qin Q, Philipp S, Alexeyev MF, Cohen MV, Downey JM. Acetylcholine and bradykinin trigger preconditioning in the heart through a pathway that includes Akt and NOS. Am J Physiol Heart Circ Physiol 2004;287:H2606-H2611.
29. Oldenburg O, Qin Q, Sharma AR, Cohen MV, Downey JM, Benoit JN. Acetylcholine leads to free radical production dependent on K(ATP) channels, G(i) proteins, phosphatidylinositol 3-kinase and tyrosine kinase. Cardiovasc Res 2002;55:544-552.
30. Qin Q, Yang XM, Cui L, Critz SD, Cohen MV, Browner NC et al. Exogenous NO triggers preconditioning via a cGMP- and mitoKATP-dependent mechanism. Am J Physiol Heart Circ Physiol 2004;287:H712-H718.
31. Pain T, Yang XM, Critz SD, Yue Y, Nakano A, Liu GS et al. Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals. Circ Res 2000;87:460-466.
32. Yue Y, Qin Q, Cohen MV, Downey JM, Critz SD. The relative order of mK(ATP) channels, free radicals and p38 MAPK in preconditioning's protective pathway in rat heart. Cardiovasc Res 2002;55:681-689.
33. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 2004;63:305-312.
34. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007;12:217- 234.
35. Budas GR, Jovanovic S, Crawford RM, Jovanovic A. Hypoxia-induced preconditioning in adult stimulated cardiomyocytes is mediated by the opening and trafficking of sarcolemmal KATP channels. FASEBJ 2004;18:1046- 1048.
36. Lin Y-F, Raab-Graham K, Jan YN, Jan LY. NO stimulation of ATP-sensitive potassium channels: involvement of Ras/mitogen-activated protein kinase pathway and contribution to neuroprotection. Proc Natl Acad Sci USA 2004;101:7799-7804.
37. Shinbo A, Iijima T. Potentiation by nitric oxide of the ATP-sensitive K+ current induced by K+ channel openers in guinea-pig ventricular cells. Br J Pharmacol 1997;120:1568-1574.
38. Ahern GP, Klyachko VA, Jackson MB. cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO. Trends Neurosci 2002;25:510-517.
39. Sun J. Protein S-nitrosylation: a role of nitric oxide signaling in cardiac ischemic preconditioning. Sheng Li Xue Bao 2007;59:544- 552.
40. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994;368:850-853.
41. Miyoshi H, Nakaya Y. Endotoxin-induced nonendothelial nitric oxide activates the Ca(2+)-activated K+ channel in cultured vascular smooth muscle cells. J Mol Cell Cardiol 1994;26:1487-1495.